Advertisement
Screener

RECURSION PHARMACEUTICALS, INC. (RXRX) Graph

RXRX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $7.67M; Cost of revenue $11.49M; Research and development $89.61M; Operating expenses (m).
  • 2026-03-31: Revenue $6.47M; Cost of revenue $12.49M; Research and development $87.90M; Operating expenses (m).
  • 2025-12-31: Revenue $35.54M*; Cost of revenue $14.28M*; Research and development $95.94M*; Operating expenses (m).
  • 2025-09-30: Revenue $5.17M; Cost of revenue $14.69M; Research and development $121.06M; Operating expenses (m).

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

RXRX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Grant$367.00KLicense And Service$7.30MRevenue$7.67MCost of revenue$11.49MOperating income-$134.97MResearch & development$89.61MPre-tax income-$131.01MIncome tax-$1.00KNet income-$131.00M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

RXRX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$7.67MRevenue$7.67MCost of revenue$11.49MOperating income-$134.97MResearch & development$89.61MPre-tax income-$131.01MIncome tax-$1.00KNet income-$131.00M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$7.67M$11.49M$89.61M(m)-$1.00K-$131.00M
2026-03-31$6.47M$12.49M$87.90M(m)-$4.60M-$117.50M
2025-12-31$35.54M*$14.28M*$95.94M*(m)$20.00K*-$108.12M*
2025-09-30$5.17M$14.69M$121.06M(m)$3.00K-$162.25M
2025-06-30$19.22M$20.16M$128.64M(m)$0.00-$171.90M
2025-03-31$14.74M$21.83M$129.63M(m)-$158.00K-$202.49M
2024-09-30$26.08M$12.08M$74.60M(m)$167.00K-$95.84M
2024-06-30$14.42M$9.20M$73.93M(m)-$523.00K-$97.54M
2024-03-31$13.79M$11.17M$67.56M(m)-$779.00K-$91.37M
2023-09-30$10.53M$10.88M$70.01M(m)$0.00-$93.02M
2023-06-30$11.02M$9.38M$55.06M(m)$0.00-$76.73M
2023-03-31$12.13M$12.45M$46.68M(m)$0.00-$65.33M
2022-09-30$13.16M$15.41M$40.84M(m)$0.00-$60.45M
2022-06-30$7.67M$14.23M$38.44M(m)$0.00-$65.56M
2022-03-31$5.33M$7.80M$32.44M(m)$0.00-$55.98M
2021-12-31(m)(m)(m)$67.49M*(m)(m)
2021-09-30$2.53M$0.00$33.25M$48.94M$0.00-$47.43M
2021-06-30$2.55M$0.00$29.62M$43.48M$0.00-$43.40M
2021-03-31$2.56M$0.00$24.11M$33.05M$0.00-$30.72M
2020-09-30$1.02M(m)$16.54M$23.50M$0.00-$23.87M
2020-06-30$186.00K(m)$13.24M$18.40M$0.00-$18.94M
2020-03-31$60.00K(m)$12.84M$18.40M$0.00-$18.42M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$14.14M$23.98M$177.51M(m)-$4.60M-$248.51M
2025-06-30$33.97M$41.99M$258.27M(m)-$158.00K-$374.38M
2024-06-30$28.21M$20.36M$141.49M(m)-$1.30M-$188.91M
2023-06-30$23.15M$21.83M$101.74M(m)$0.00-$142.05M
2022-06-30$13.01M$22.03M$70.88M(m)$0.00-$121.54M
2021-06-30$5.11M$0.00$53.73M$76.52M$0.00-$74.12M
2020-06-30$246.00K(m)$26.09M$36.81M$0.00-$37.37M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$39.14M$56.68M$379.33M(m)-$156.00K-$536.64M
2024-09-30$54.29M$32.44M$216.09M(m)-$1.13M-$284.75M
2023-09-30$33.68M$32.71M$171.74M(m)$0.00-$235.07M
2022-09-30$26.17M$37.44M$111.72M(m)$0.00-$181.98M
2021-09-30$7.64M$0.00$86.98M$125.46M$0.00-$121.55M
2020-09-30$1.27M(m)$42.62M$60.30M$0.00-$61.24M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$74.68M$70.95M$475.27M(m)-$136.00K-$644.76M
2024-12-31$58.84M$45.24M$314.42M(m)-$1.13M-$463.66M
2023-12-31$44.58M$42.59M$241.23M(m)-$4.06M-$328.07M
2022-12-31$39.84M$48.27M$155.70M(m)$0.00-$239.48M
2021-12-31$10.18M$0.00$135.27M$192.95M$0.00-$186.48M
2020-12-31$3.96M$0.00$63.32M$88.58M$0.00-$87.01M
2019-12-31$2.32M(m)$45.81M$64.76M$0.00-$61.88M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Vericel Corp (VCEL)United States$2.011B93.97
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Greenland Mines Ltd (GRML)United States$2.362B
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Immunocore Holdings plc (IMCR)$1.613B-90.43
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51